Term,Overlap,P-value,Adjusted P-value,Old P-value,Old Adjusted P-value,Odds Ratio,Combined Score,Genes
Pathways in cancer,31/531,1.544068281953706E-15,3.41239090311769E-13,0,0,7.166011976047904,244.39222152651354,EPAS1;LAMA4;LAMA3;CXCR4;PIK3R1;LAMC1;EGFR;FOXO1;GNG2;CCND2;CCND1;E2F2;ELOB;FADD;STAT5A;STAT5B;TCF7L2;JUN;FZD4;STAT1;TPM3;ZBTB16;HGF;FOS;ESR1;TGFBR2;CXCL12;KIT;PPARG;FGFR3;MET
Focal adhesion,18/201,1.6094853333949264E-12,1.7784812934013937E-10,0,0,10.720765027322404,291.12351775874413,JUN;VWF;CAV2;HGF;CAV1;LAMA4;LAMA3;PARVA;PIK3R1;LAMC1;EGFR;MYLK;COL1A2;CCND2;CCND1;KDR;SPP1;MET
PI3K-Akt signaling pathway,22/354,7.841690455662326E-12,5.776711969004581E-10,0,0,7.330572289156627,187.4542181347836,VWF;HGF;LAMA4;LAMA3;PIK3R1;LAMC1;EGFR;EFNA1;GHR;NR4A1;COL1A2;GNG2;CCND2;CCND1;PPP2R1B;KIT;KDR;SPP1;SGK1;TLR4;FGFR3;MET
Proteoglycans in cancer,16/205,2.297452799676112E-10,1.2693426718210519E-8,0,0,9.122855979998837,202.4731208425284,FZD4;CAV2;HGF;CAV1;ANK2;PIK3R1;ESR1;EGFR;DCN;COL1A2;CCND1;PLAU;KDR;EZR;TLR4;MET
AGE-RAGE signaling pathway in diabetic complications,11/100,4.454326007695626E-9,1.9541249795677618E-7,0,0,13.029081295439525,250.54128656747474,STAT5A;EGR1;STAT5B;JUN;COL1A2;CCND1;STAT1;CCL2;PIK3R1;FOXO1;TGFBR2
Human papillomavirus infection,18/331,5.701734672359736E-9,1.9541249795677618E-7,0,0,6.226517571884984,118.19484104129904,TCF7L2;MAML2;VWF;FZD4;STAT1;LAMA4;LAMA3;PIK3R1;LAMC1;EGFR;FOXO1;PARD6B;COL1A2;CCND2;CCND1;PPP2R1B;SPP1;FADD
MAPK signaling pathway,17/294,6.189536134377526E-9,1.9541249795677618E-7,0,0,6.620360213016335,125.1274938463081,JUN;MEF2C;DUSP1;HGF;FOS;EGFR;CDC25B;TGFBR2;EFNA1;NR4A1;RPS6KA3;KIT;MAPKAPK2;KDR;MAP3K20;FGFR3;MET
JAK-STAT signaling pathway,13/162,8.437830528858331E-9,2.330950683597114E-7,0,0,9.268601487393434,172.3083123282026,STAT5A;STAT5B;STAT1;FHL1;LIFR;PIK3R1;EGFR;GHR;SOCS3;CCND2;CCND1;LEP;LEPR
Fluid shear stress and atherosclerosis,12/139,1.4107465443984798E-8,3.464166514578489E-7,0,0,9.99491998983998,180.6737880384923,CDH5;MEF2C;JUN;CAV2;DUSP1;CAV1;KDR;PECAM1;CCL2;PIK3R1;FOS;BMPR1B
Prolactin signaling pathway,9/70,2.9401758056364662E-8,6.497788530456591E-7,0,0,15.410616705698672,267.2541721991754,STAT5A;SOCS3;STAT5B;CCND2;CCND1;STAT1;FOS;PIK3R1;ESR1
Human T-cell leukemia virus 1 infection,14/219,4.067394310681299E-8,8.171764933277881E-7,0,0,7.273541887592789,123.77879498474726,STAT5A;STAT5B;EGR1;NRP1;JUN;PIK3R1;FOS;ETS2;TGFBR2;ZFP36;CCND2;CCND1;E2F2;CALR
Transcriptional misregulation in cancer,13/192,6.417339758929623E-8,1.0989921497899745E-6,0,0,7.703427449796165,127.581677831904,MEF2C;ZBTB16;LMO2;RUNX2;FOXO1;FLI1;TGFBR2;CCND2;MAF;BCL6;PLAU;PPARG;MET
Kaposi sarcoma-associated herpesvirus infection,13/193,6.821711373153906E-8,1.0989921497899745E-6,0,0,7.66024024024024,126.39833312826295,TCF7L2;JUN;STAT1;PIK3R1;FOS;C3;RCAN1;ZFP36;GNG2;CCND1;MAPKAPK2;E2F2;FADD
Chagas disease,10/102,6.961941220388979E-8,1.0989921497899745E-6,0,0,11.395698427382055,187.80364445831427,C3;JUN;PPP2R1B;CCL2;PIK3R1;FADD;CALR;FOS;TLR4;TGFBR2
FoxO signaling pathway,11/131,7.644301833884785E-8,1.126260470192358E-6,0,0,9.648039215686275,158.09971941456888,CCND2;CCND1;BCL6;PLK1;S1PR1;IRS2;PIK3R1;SGK1;FOXO1;EGFR;TGFBR2
Complement and coagulation cascades,9/85,1.638206641534491E-7,2.2627729236195156E-6,0,0,12.359649122807017,193.1132576127208,C3;F8;VWF;CFH;PLAU;PROS1;F13A1;SERPING1;A2M
AMPK signaling pathway,10/120,3.251960495013749E-7,4.2275486435178735E-6,0,0,9.522243713733076,142.2512524961279,SREBF1;CCND1;PPP2R1B;LEP;LEPR;IRS2;PPARG;PIK3R1;CD36;FOXO1
Non-small cell lung cancer,8/72,5.574161685367377E-7,6.791497589246522E-6,0,0,12.985526315789473,186.99097791561474,STAT5A;STAT5B;CCND1;HGF;E2F2;PIK3R1;MET;EGFR
Malaria,7/50,5.838844081252666E-7,6.791497589246522E-6,0,0,16.84074028978449,241.72462343214116,LRP1;HGF;PECAM1;CCL2;CD36;MET;TLR4
Estrogen signaling pathway,10/137,1.1108687111558705E-6,1.227509925827237E-5,0,0,8.240492544814877,112.98018715356785,JUN;KRT19;KRT18;KRT15;PIK3R1;FOS;FKBP4;ESR1;CTSD;EGFR
Measles,10/139,1.2686180999799613E-6,1.335069524264626E-5,0,0,8.111908296222992,110.14010299009385,STAT5A;STAT5B;JUN;CCND2;CCND1;STAT1;PIK3R1;FADD;FOS;TLR4
TNF signaling pathway,9/112,1.7374931114460933E-6,1.7453908074072117E-5,0,0,9.107258437355524,120.79018088235966,SOCS3;CXCL10;JUN;MMP14;BCL3;CCL2;PIK3R1;FADD;FOS
Breast cancer,10/147,2.1118671207803446E-6,2.0292288421411135E-5,0,0,7.635114148159652,99.775199153965,TCF7L2;JUN;CCND1;FZD4;KIT;E2F2;PIK3R1;FOS;ESR1;EGFR
MicroRNAs in cancer,14/310,2.7281146185959894E-6,2.5121388779571405E-5,0,0,5.014027614571093,64.23921940862009,IRS2;PIK3R1;EGFR;CDC25B;EFNA1;ZEB2;CCND2;CCND1;PLAU;E2F2;VIM;EZR;FGFR3;MET
Coronavirus disease,12/232,3.6134121433963535E-6,3.1942563347623765E-5,0,0,5.742521994134897,71.95872789982765,C3;NRP1;CXCL10;JUN;VWF;STAT1;F13A1;CCL2;PIK3R1;FOS;TLR4;EGFR
Acute myeloid leukemia,7/67,4.410731084935471E-6,3.749121422195151E-5,0,0,12.058813263525305,148.70289524102333,STAT5A;STAT5B;TCF7L2;CCND1;ZBTB16;KIT;PIK3R1
Hepatitis B,10/162,5.056215550957711E-6,4.1386060620802005E-5,0,0,6.876399776035834,83.85695446955533,STAT5A;STAT5B;JUN;STAT1;E2F2;PIK3R1;FADD;FOS;TLR4;TGFBR2
Hippo signaling pathway,10/163,5.340875591079926E-6,4.215476805816656E-5,0,0,6.831108329856765,82.9304813474678,YAP1;TCF7L2;PARD6B;CCND2;CCND1;PPP2R1B;FZD4;BMPR1B;TEAD1;TGFBR2
Epstein-Barr virus infection,11/202,5.683449933635078E-6,4.331180811494318E-5,0,0,6.0397289805974745,72.9475574872952,CXCL10;JUN;CCND2;CCND1;STAT1;E2F2;TAP1;VIM;PIK3R1;CALR;FADD
Toll-like receptor signaling pathway,8/104,9.157633800713984E-6,6.746123566525968E-5,0,0,8.64298245614035,100.26657164207714,CXCL10;JUN;STAT1;SPP1;PIK3R1;FADD;FOS;TLR4
Pancreatic cancer,7/76,1.0286135113750025E-5,7.333018903673405E-5,0,0,10.481144244631611,120.3729406360067,CCND1;STAT1;E2F2;PIK3R1;EGFR;TGFBR2;ARHGEF6
Axon guidance,10/182,1.4092959574522636E-5,9.732950206154695E-5,0,0,6.070633349826818,67.80797411505942,EFNA1;NRP1;ABLIM1;PARD6B;CXCL12;DPYSL2;CXCR4;PIK3R1;BMPR1B;MET
Human cytomegalovirus infection,11/225,1.5726689369269115E-5,1.0532116213965075E-4,0,0,5.384277075316108,59.55091925069347,GNG2;CXCL12;CCND1;E2F2;CXCR4;TAP1;CCL2;PIK3R1;CALR;FADD;EGFR
Gastric cancer,9/149,1.8007135619051358E-5,1.1704638152383382E-4,0,0,6.687755102040816,73.06200209419822,TCF7L2;CCND1;FZD4;HGF;E2F2;PIK3R1;MET;EGFR;TGFBR2
Chemokine signaling pathway,10/192,2.2389170152187226E-5,1.4137161724666792E-4,0,0,5.734159457563713,61.395262220762454,STAT5B;CXCL10;GRK3;CXCL12;CCL11;GNG2;STAT1;CXCR4;CCL2;PIK3R1
Colorectal cancer,7/86,2.325992265067654E-5,1.427900807166532E-4,0,0,9.149777983961826,97.61695679717262,TCF7L2;JUN;CCND1;FOS;PIK3R1;EGFR;TGFBR2
"Growth hormone synthesis, secretion and action",8/119,2.4573751710280834E-5,1.4337693738598764E-4,0,0,7.4693219535324795,79.27812604071747,STAT5A;GHR;SOCS3;STAT5B;STAT1;IRS2;PIK3R1;FOS
Non-alcoholic fatty liver disease,9/155,2.4653048057319144E-5,1.4337693738598764E-4,0,0,6.410958904109589,68.02418473240843,SOCS3;SREBF1;JUN;LEP;LEPR;IRS2;PPARG;PIK3R1;FOS
ECM-receptor interaction,7/88,2.7027255979773098E-5,1.4823324570679747E-4,0,0,8.9229526210329,93.85754693675439,COL1A2;VWF;LAMA4;LAMA3;SPP1;LAMC1;CD36
Hepatitis C,9/157,2.728663898215993E-5,1.4823324570679747E-4,0,0,6.3236808236808235,66.45627881917045,SOCS3;CXCL10;CCND1;PPP2R1B;STAT1;E2F2;PIK3R1;FADD;EGFR
Chemical carcinogenesis,11/239,2.750028540261853E-5,1.4823324570679747E-4,0,0,5.050051599587204,53.03217844757278,STAT5A;STAT5B;RPS6KA3;JUN;CCND1;BCL6;PIK3R1;FOS;KLF4;ESR1;EGFR
Th1 and Th2 cell differentiation,7/92,3.6075450769441165E-5,1.8982558619158328E-4,0,0,8.501324299353248,86.96768009059814,STAT5A;STAT5B;JUN;MAF;MAML2;STAT1;FOS
Osteoclast differentiation,8/127,3.926506216567808E-5,2.018041567119734E-4,0,0,6.964352056612118,70.65457342566314,SOCS3;JUN;STAT1;SIRPA;PPARG;PIK3R1;FOS;TGFBR2
IL-17 signaling pathway,7/94,4.145494513554313E-5,2.0821688352170526E-4,0,0,8.30504904615755,83.80544748983375,CXCL10;JUN;CCL11;CCL2;FOS;FADD;S100A8
Relaxin signaling pathway,8/129,4.390709481251722E-5,2.1563262119036236E-4,0,0,6.848542844715094,68.7144069973048,ACTA2;JUN;COL1A2;GNG2;PIK3R1;FOS;EGFR;TGFBR2
Hepatocellular carcinoma,9/168,4.644070805748099E-5,2.231173147978978E-4,0,0,5.882899071578317,58.69564983454075,TCF7L2;CCND1;FZD4;HGF;E2F2;PIK3R1;MET;EGFR;TGFBR2
Prostate cancer,7/97,5.074437743203834E-5,2.386065406910739E-4,0,0,8.026992437463642,79.37659826470869,TCF7L2;CCND1;PLAU;E2F2;PIK3R1;FOXO1;EGFR
Human immunodeficiency virus 1 infection,10/212,5.202928320463965E-5,2.3955149142136173E-4,0,0,5.161154413313672,50.90809870522642,JUN;GNG2;CXCR4;TAP1;ELOB;PIK3R1;CALR;FADD;FOS;TLR4
Renal cell carcinoma,6/69,6.229592696368359E-5,2.809673440606954E-4,0,0,9.791170634920634,94.81392205074602,JUN;EPAS1;HGF;ELOB;PIK3R1;MET
Insulin signaling pathway,8/137,6.731255756336369E-5,2.975215044300675E-4,0,0,6.421215830273358,61.68325072609794,SOCS3;SREBF1;PRKAR2B;IRS2;PIK3R1;SORBS1;FOXO1;RHOQ
Adherens junction,6/71,7.321633333453424E-5,3.1727077778298166E-4,0,0,9.488942307692307,90.35458191078816,TCF7L2;PTPRB;SORBS1;MET;EGFR;TGFBR2
Melanoma,6/72,7.922093534847752E-5,3.366889752310295E-4,0,0,9.344696969696969,88.24449616864777,CCND1;HGF;E2F2;PIK3R1;MET;EGFR
Insulin resistance,7/108,1.0051707957585399E-4,4.1913725634459874E-4,0,0,7.148774039707636,65.80577253824497,RPS6KA3;SOCS3;SREBF1;IRS2;PIK3R1;CD36;FOXO1
Chronic myeloid leukemia,6/76,1.0727971646285191E-4,4.3905217293130133E-4,0,0,8.808928571428572,80.51423224167704,STAT5A;STAT5B;CCND1;E2F2;PIK3R1;TGFBR2
Ras signaling pathway,10/232,1.1014705550991237E-4,4.425908957761934E-4,0,0,4.691393521180755,42.75592600230843,EFNA1;GNG2;HGF;KIT;KDR;PIK3R1;FGFR3;MET;EGFR;ETS2
Oxytocin signaling pathway,8/154,1.522827581299836E-4,6.009730276201139E-4,0,0,5.668637346791637,49.82602707621736,RCAN1;RGS2;MEF2C;JUN;CCND1;FOS;EGFR;MYLK
Cytokine-cytokine receptor interaction,11/295,1.8048411411090162E-4,6.99771740675601E-4,0,0,4.042667771333885,34.847261726106964,GHR;CXCL10;CCL11;CXCL12;LEP;LEPR;CXCR4;CCL2;LIFR;BMPR1B;TGFBR2
Viral carcinogenesis,9/203,1.970083802930587E-4,7.506698628407926E-4,0,0,4.812960235640648,41.065448750501595,C3;STAT5A;STAT5B;JUN;GSN;CCND2;CCND1;MAPKAPK2;PIK3R1
Thyroid hormone signaling pathway,7/121,2.0433005692428315E-4,7.653719081401114E-4,0,0,6.329383668595573,53.7730128624302,RCAN1;THRB;CCND1;STAT1;PIK3R1;ESR1;FOXO1
Rap1 signaling pathway,9/210,2.534783601769735E-4,9.289457028272671E-4,0,0,4.6436863302534945,38.45080062695997,EFNA1;PARD6B;HGF;KIT;KDR;PIK3R1;FGFR3;MET;EGFR
PD-L1 expression and PD-1 checkpoint pathway in cancer,6/89,2.564058274772095E-4,9.289457028272671E-4,0,0,7.424322289156627,61.38985828448088,JUN;STAT1;FOS;PIK3R1;TLR4;EGFR
Small cell lung cancer,6/92,3.070183682408807E-4,0.0010943719255037845,0,0,7.164244186046512,57.94872687817255,CCND1;LAMA4;LAMA3;E2F2;LAMC1;PIK3R1
Regulation of actin cytoskeleton,9/218,3.3383726764794056E-4,0.001171079938891982,0,0,4.464114832535885,35.73460044787522,GSN;CXCL12;CXCR4;PIK3R1;EZR;FGFR3;EGFR;MYLK;ARHGEF6
Apelin signaling pathway,7/137,4.3591406257180736E-4,0.001482107812744145,0,0,5.545871929118002,42.914319899590815,ACTA2;EGR1;MEF2C;GNG2;CCND1;SPP1;MYLK
Yersinia infection,7/137,4.3591406257180736E-4,0.001482107812744145,0,0,5.545871929118002,42.914319899590815,RPS6KA3;JUN;CCL2;PIK3R1;FOS;TLR4;SKAP2
Thyroid cancer,4/37,4.7655216121314E-4,0.0015957276913349083,0,0,12.351765073414558,94.47782809126898,TCF7L2;CCND1;TPM3;PPARG
Amoebiasis,6/102,5.343550611785118E-4,0.0017625741570216583,0,0,6.414713541666667,48.33133864532886,COL1A2;LAMA4;LAMA3;PIK3R1;LAMC1;TLR4
Adipocytokine signaling pathway,5/69,6.08016016401652E-4,0.001976052053305369,0,0,7.989799222797927,59.1669347580093,SOCS3;LEP;LEPR;IRS2;CD36
Central carbon metabolism in cancer,5/70,6.495881958179432E-4,0.002068725024346622,0,0,7.866480669589478,57.733454202659594,KIT;PIK3R1;MET;FGFR3;EGFR
"Parathyroid hormone synthesis, secretion and action",6/106,6.552522701550386E-4,0.002068725024346622,0,0,6.156875,45.132912165378904,EGR1;MEF2C;MMP14;FOS;RUNX2;EGFR
Th17 cell differentiation,6/107,6.885474200978229E-4,0.002143225068191815,0,0,6.095606435643564,44.38166162415926,STAT5A;STAT5B;JUN;STAT1;FOS;TGFBR2
Bladder cancer,4/41,7.085244863093272E-4,0.0021747765482550184,0,0,11.014210086375035,79.87864150321772,CCND1;E2F2;FGFR3;EGFR
HIF-1 signaling pathway,6/109,7.590568292184352E-4,0.0022979665651681395,0,0,5.976638349514563,42.93278658511529,TF;ELOB;PIK3R1;TIMP1;TLR4;EGFR
PPAR signaling pathway,5/74,8.374677947357063E-4,0.0025010862518458255,0,0,7.408950964932042,52.493364073000755,FABP4;LPL;PPARG;CD36;SORBS1
Cushing syndrome,7/155,9.07811592693854E-4,0.0026750181598045567,0,0,4.86691665487477,34.09018969907158,NR4A1;TCF7L2;RASD1;CCND1;FZD4;E2F2;EGFR
Cellular senescence,7/156,9.426415742604417E-4,0.0026783634200378053,0,0,4.834006816824203,33.67767682735449,CCND2;CCND1;MAPKAPK2;E2F2;PIK3R1;FOXO1;TGFBR2
Endocytosis,9/252,9.449728791938773E-4,0.0026783634200378053,0,0,3.832843425436018,26.693279706715014,PARD6B;ARF1;GRK3;CAV2;CAV1;CXCR4;FGFR3;EGFR;TGFBR2
Pertussis,5/76,9.453047364839312E-4,0.0026783634200378053,0,0,7.199518353645187,50.13746892512262,C3;JUN;SERPING1;FOS;TLR4
Leukocyte transendothelial migration,6/114,9.598081385557998E-4,0.002685032893934579,0,0,5.69849537037037,39.59757441415097,CDH5;CXCL12;PECAM1;CXCR4;PIK3R1;EZR
Leishmaniasis,5/77,0.001002937441275655,0.002770614681523997,0,0,7.099165227403569,49.018473262946344,C3;JUN;STAT1;FOS;TLR4
Lipid and atherosclerosis,8/215,0.0013911997289158538,0.0037957424702518973,0,0,3.9857615052123063,26.216700195423375,ABCA1;JUN;CCL2;PPARG;PIK3R1;CD36;FOS;TLR4
Tight junction,7/169,0.0014986757620709052,0.004003139800068973,0,0,4.443151703186607,28.894585906478202,JUN;PARD6B;CCND1;PPP2R1B;AMOTL2;EZR;MPDZ
Cholesterol metabolism,4/50,0.0015034416443697955,0.004003139800068973,0,0,8.855221873599282,57.55892773976394,ABCA1;LRP1;LPL;CD36
ErbB signaling pathway,5/85,0.001562453459054429,0.004110740648226533,0,0,6.386658031088083,41.26737785826921,STAT5A;STAT5B;JUN;PIK3R1;EGFR
Influenza A,7/172,0.0016573891814675628,0.004309211871815663,0,0,4.3617007774075836,27.925840246089752,SOCS3;CXCL10;STAT1;CCL2;PIK3R1;FADD;TLR4
NOD-like receptor signaling pathway,7/181,0.002212996683397085,0.0056868868259390215,0,0,4.1341999157489315,25.274049666928196,JUN;STAT1;TXNIP;CCL2;FADD;ANTXR2;TLR4
Rheumatoid arthritis,5/93,0.00232329953629025,0.005901714914024659,0,0,5.803697597739048,35.19807302902893,JUN;CXCL12;CCL2;FOS;TLR4
Staphylococcus aureus infection,5/95,0.00254940760683789,0.006402489558081518,0,0,5.674150834772597,33.885428788320105,C3;KRT19;KRT18;CFH;KRT15
Endometrial cancer,4/58,0.0026047593316359794,0.006467997890916308,0,0,7.5402825505918285,44.86781035657885,TCF7L2;CCND1;PIK3R1;EGFR
Signaling pathways regulating pluripotency of stem cells,6/143,0.003037471316447861,0.007458679565944192,0,0,4.485629562043796,26.001983063200683,FZD4;LIFR;PIK3R1;BMPR1B;KLF4;FGFR3
Viral protein interaction with cytokine and cytokine receptor,5/100,0.0031840642542200646,0.007732727474534442,0,0,5.374147804745023,30.899183186725125,CXCL10;CXCL12;CCL11;CXCR4;CCL2
Longevity regulating pathway,5/102,0.003467263580455342,0.00832897012261555,0,0,5.26280647401314,29.81058620377177,IRS2;PPARG;PIK3R1;CRYAB;FOXO1
C-type lectin receptor signaling pathway,5/104,0.0037681299884365417,0.008954373413381459,0,0,5.155963782906788,28.77634351264471,JUN;STAT1;MAPKAPK2;BCL3;PIK3R1
Inflammatory bowel disease,4/65,0.003939689946421906,0.009262462533608948,0,0,6.672638161230354,36.944083778601154,JUN;MAF;STAT1;TLR4
Toxoplasmosis,5/112,0.005160236038970023,0.012004338574867107,0,0,4.768534211418333,25.114787027074176,STAT1;LAMA4;LAMA3;LAMC1;TLR4
Glioma,4/75,0.006552757758754076,0.015084994423798447,0,0,5.7299259474372,28.809318682593226,CCND1;E2F2;PIK3R1;EGFR
Neurotrophin signaling pathway,5/119,0.006647876667002586,0.01514619323100589,0,0,4.4741387146623035,22.43090551872311,RPS6KA3;JUN;MAGED1;MAPKAPK2;PIK3R1
Bacterial invasion of epithelial cells,4/77,0.007185454361582799,0.016203932794997947,0,0,5.572376782940263,27.503560717588353,CAV2;CAV1;PIK3R1;MET
Cell cycle,5/124,0.007878927476310874,0.017588312851158618,0,0,4.285061174728959,20.75496586451663,CCND2;CCND1;PLK1;E2F2;CDC25B
Calcium signaling pathway,7/240,0.010122928592675067,0.022371672189811898,0,0,3.0780621531132732,14.137392554447967,HGF;KDR;CXCR4;FGFR3;MET;EGFR;MYLK
Type II diabetes mellitus,3/46,0.010614210649157109,0.02322515399469031,0,0,7.069409660107334,32.134436721037815,SOCS3;IRS2;PIK3R1
Shigellosis,7/246,0.01148311307861508,0.024880078336999338,0,0,2.999868562290521,13.400046136089044,C3;JUN;ARF1;PIK3R1;TLR4;EGFR;FOXO1
Salmonella infection,7/249,0.01221076581188883,0.026199798489586715,0,0,2.9622257799316345,13.049899861270797,TCF7L2;JUN;ARF1;KLC2;FADD;FOS;TLR4
Apoptosis,5/142,0.0136134327977718,0.02885995264992406,0,0,3.718656631746152,15.977945508843312,JUN;PIK3R1;FADD;FOS;CTSD
GnRH signaling pathway,4/93,0.013728517068990803,0.02885995264992406,0,0,4.566894474690143,19.58412256520565,EGR1;MMP14;JUN;EGFR
Pathogenic Escherichia coli infection,6/197,0.013842330230280317,0.02885995264992406,0,0,3.2086060209424083,13.73291069187258,JUN;ARF1;FADD;FOS;EZR;TLR4
TGF-beta signaling pathway,4/94,0.014230476839340207,0.02939191945321669,0,0,4.515922107674685,19.2033687937959,PPP2R1B;BMPR1B;DCN;TGFBR2
Circadian entrainment,4/97,0.01580564630690436,0.03234303549838762,0,0,4.36958208624321,18.122352491235524,PER1;GNG2;RASD1;FOS
Choline metabolism in cancer,4/98,0.016354060865679677,0.03315823349830467,0,0,4.322877824084229,17.781202752720034,JUN;PIK3R1;FOS;EGFR
Regulation of lipolysis in adipocytes,3/55,0.017196707468804112,0.03454974864187008,0,0,5.84319526627219,23.74112055013548,FABP4;IRS2;PIK3R1
Progesterone-mediated oocyte maturation,4/100,0.017486372614794122,0.03481521034116668,0,0,4.232388316151202,17.125654244050143,RPS6KA3;PLK1;PIK3R1;CDC25B
Phagosome,5/152,0.017775596327641724,0.035075060610793046,0,0,3.4639244298755774,13.959368665739063,C3;TAP1;CALR;CD36;TLR4
Hedgehog signaling pathway,3/56,0.01804049737404705,0.03528274265189733,0,0,5.732656023222061,23.017394687188755,GRK3;CCND2;CCND1
Legionellosis,3/57,0.01890698326246999,0.036653011412332175,0,0,5.626210826210826,22.326064494152536,C3;ARF1;TLR4
VEGF signaling pathway,3/59,0.02070816364581049,0.03979568839760103,0,0,5.424725274725275,21.032892807745707,MAPKAPK2;KDR;PIK3R1
Necroptosis,5/159,0.021142029329160792,0.040279211049521854,0,0,3.305295740528901,12.746847600305095,STAT5A;STAT5B;STAT1;FADD;TLR4
Viral myocarditis,3/60,0.021642897959238256,0.04088102947856115,0,0,5.329284750337382,20.427563690905835,CCND1;CAV1;DMD
Wnt signaling pathway,5/166,0.024899587844699565,0.04663397384473393,0,0,3.1604608502558493,11.671278604467908,TCF7L2;JUN;CCND2;CCND1;FZD4
Sphingolipid signaling pathway,4/119,0.030689992591719423,0.05699570052747893,0,0,3.5297176154190946,12.296896063976588,PPP2R1B;S1PR1;PIK3R1;CTSD
Alzheimer disease,8/369,0.03099626697407099,0.0570847916772474,0,0,2.2675025513923313,7.877051041399943,KLC2;LRP1;MME;FZD4;LPL;IRS2;PIK3R1;FADD
Epithelial cell signaling in Helicobacter pylori infection,3/70,0.032240602824136856,0.058885729125076405,0,0,4.531572904707233,15.563817031954146,JUN;MET;EGFR
Tuberculosis,5/180,0.03364008413978711,0.06093818520404059,0,0,2.9055514433752774,9.855737834837814,C3;STAT1;FADD;CTSD;TLR4
Platelet activation,4/124,0.03492327266633233,0.0627483191809711,0,0,3.381786941580756,11.344548674513174,COL1A2;VWF;PIK3R1;MYLK
B cell receptor signaling pathway,3/81,0.04648439109138168,0.0828471808967367,0,0,3.8903353057199213,11.93803346808487,JUN;FOS;PIK3R1
Diabetic cardiomyopathy,5/203,0.051709844915919914,0.09084439267471814,0,0,2.5650285235777464,7.5978891800779955,COL1A2;PIK3R1;CD36;CTSD;TGFBR2
Aldosterone-regulated sodium reabsorption,2/37,0.051793635642599485,0.09084439267471814,0,0,5.762973760932945,17.061214671092433,PIK3R1;SGK1
Neuroactive ligand-receptor interaction,7/341,0.05365161467240888,0.09336225860316821,0,0,2.1361883562717496,6.248871560993032,C3;GHR;THRB;LEP;S1PR1;LEPR;NR3C1
Prion disease,6/273,0.05476369218489602,0.09455293728798453,0,0,2.2863998127340825,6.641369225962622,EGR1;KLC2;CAV2;CAV1;PIK3R1;LAMC1
Phospholipase D signaling pathway,4/148,0.0597346584876649,0.10233612035483676,0,0,2.8147193585337917,7.931436911670672,ARF1;KIT;PIK3R1;EGFR
mTOR signaling pathway,4/154,0.06708792293391805,0.11403744809589628,0,0,2.7013058419243987,7.298256400706165,RPS6KA3;FZD4;PIK3R1;SGK1
Fat digestion and absorption,2/43,0.06759685837358557,0.11403744809589628,0,0,4.918118466898955,13.250364137460942,ABCA1;CD36
ABC transporters,2/45,0.07317652182093962,0.1225152372911186,0,0,4.688894162316089,12.260898613128823,ABCA1;TAP1
Hematopoietic cell lineage,3/99,0.07530024677639337,0.12512296644799198,0,0,3.1580128205128206,8.167479713124104,MME;KIT;CD36
Melanogenesis,3/101,0.07889497825568491,0.13011783727243556,0,0,3.0932496075353217,7.855733319132799,TCF7L2;FZD4;KIT
Intestinal immune network for IgA production,2/48,0.08181072190551267,0.13392718178606147,0,0,4.382431233362911,10.970745946307456,CXCL12;CXCR4
Protein digestion and absorption,3/103,0.08256345325766513,0.13416561154370585,0,0,3.031076923076923,7.560076145928414,COL17A1;COL1A2;MME
NF-kappa B signaling pathway,3/104,0.08442489877948275,0.1344168461836447,0,0,3.000913937547601,7.417937890699555,CXCL12;PLAU;TLR4
T cell receptor signaling pathway,3/104,0.08442489877948275,0.1344168461836447,0,0,3.000913937547601,7.417937890699555,JUN;PIK3R1;FOS
cGMP-PKG signaling pathway,4/167,0.0845427222603014,0.1344168461836447,0,0,2.4842198469420023,6.137260867723485,RGS2;MEF2C;IRS2;MYLK
Protein processing in endoplasmic reticulum,4/171,0.09031976886450205,0.14257620656467823,0,0,2.424223717513427,5.82880088390595,PPP1R15A;DNAJC1;CALR;CRYAB
Cholinergic synapse,3/113,0.10196100060169108,0.15981121370903353,0,0,2.754125874125874,6.288123487024435,GNG2;PIK3R1;FOS
Notch signaling pathway,2/59,0.11580812452808689,0.18023658817399438,0,0,3.5347296813462226,7.6202429080226235,MAML2;DTX1
Neutrophil extracellular trap formation,4/189,0.11853968166913981,0.18319768985230697,0,0,2.186347171914182,4.662401759323885,C3;VWF;PIK3R1;TLR4
Glycerolipid metabolism,2/61,0.1223248600244283,0.18665708539096262,0,0,3.414562435143549,7.174251720956937,ALDH2;LPL
Herpes simplex virus 1 infection,8/498,0.12246731846918363,0.18665708539096262,0,0,1.6594629430719656,3.4847246087233343,C3;SOCS3;STAT1;TAP1;CCL2;PIK3R1;CALR;FADD
Basal cell carcinoma,2/63,0.12892888030731356,0.19515946950627602,0,0,3.3022750083640013,6.764691670684913,TCF7L2;FZD4
GnRH secretion,2/64,0.13226176364444261,0.19884251541103276,0,0,3.248847926267281,6.572329238772686,SPP1;PIK3R1
Oocyte meiosis,3/129,0.13628291474652712,0.20350354161474657,0,0,2.4024420024420023,4.7881204817013945,RPS6KA3;PPP2R1B;PLK1
Dopaminergic synapse,3/132,0.14311394606993147,0.21226967839902586,0,0,2.3462134764460347,4.561306795851138,GNG2;PPP2R1B;FOS
Amphetamine addiction,2/69,0.14920640519815692,0.21983077032528453,0,0,3.0056350898568382,5.717994319469603,JUN;FOS
RIG-I-like receptor signaling pathway,2/70,0.15264657758572944,0.22340989169831924,0,0,2.961284513805522,5.566119151638943,CXCL10;FADD
Autophagy,3/137,0.15474446270669953,0.22484975875858473,0,0,2.258094144661309,4.2135588513196165,IRS2;PIK3R1;CTSD
Nitrogen metabolism,1/17,0.15566521760209712,0.22484975875858473,0,0,6.277284263959391,11.676047647649668,CA12
Ubiquitin mediated proteolysis,3/140,0.16186119657228895,0.23228132754854455,0,0,2.2083099382369453,4.021368000574755,SOCS3;UBE2L6;ELOB
p53 signaling pathway,2/73,0.16305775708765646,0.23248880204111017,0,0,2.835728657660247,5.143021556990856,CCND2;CCND1
Gastric acid secretion,2/76,0.17359183405203202,0.24592176490704537,0,0,2.720353006067292,4.763470096264379,EZR;MYLK
Arrhythmogenic right ventricular cardiomyopathy,2/77,0.1771276934917909,0.2493326131317566,0,0,2.6839455782312927,4.64559946298882,TCF7L2;DMD
Antigen processing and presentation,2/78,0.18067483439031992,0.25199534483340796,0,0,2.648496240601504,4.531726332759098,TAP1;CALR
Cell adhesion molecules,3/148,0.18129981822856048,0.25199534483340796,0,0,2.0856233421750665,3.561417017639496,CDH5;VCAN;PECAM1
Pantothenate and CoA biosynthesis,1/21,0.1886376234670404,0.2605557174138496,0,0,5.020812182741117,8.374350413278753,ALDH2
Histidine metabolism,1/22,0.19667854246153751,0.2699748936894397,0,0,4.781484167270969,7.77557614353097,ALDH2
Proximal tubule bicarbonate reclamation,1/23,0.20464017128814416,0.27745691935386413,0,0,4.56391324411629,7.240657964857908,AQP1
Renin-angiotensin system,1/23,0.20464017128814416,0.27745691935386413,0,0,4.56391324411629,7.240657964857908,MME
Hypertrophic cardiomyopathy,2/90,0.22392419754529538,0.30175151010677004,0,0,2.285946196660482,3.4207989013747016,TPM3;DMD
Morphine addiction,2/91,0.22756999547526713,0.304805872727479,0,0,2.260146755331346,3.345689400553753,GRK3;GNG2
Dilated cardiomyopathy,2/96,0.24585361218265625,0.32731113429136766,0,0,2.139383412939644,3.001595560816009,TPM3;DMD
Fc gamma R-mediated phagocytosis,2/97,0.24951830635914535,0.3302008724872523,0,0,2.1167561761546723,2.938529597067055,GSN;PIK3R1
Ascorbate and aldarate metabolism,1/30,0.2582158467438044,0.3376668765111288,0,0,3.4610537370908454,4.686126340024527,ALDH2
beta-Alanine metabolism,1/30,0.2582158467438044,0.3376668765111288,0,0,3.4610537370908454,4.686126340024527,ALDH2
Asthma,1/31,0.2655705309713454,0.34322273300975054,0,0,3.3455160744500847,4.435735523700054,CCL11
Circadian rhythm,1/31,0.2655705309713454,0.34322273300975054,0,0,3.3455160744500847,4.435735523700054,PER1
Glucagon signaling pathway,2/107,0.28619716807638196,0.36773008223767684,0,0,1.9141885325558794,2.394792091490246,PPP4C;FOXO1
Serotonergic synapse,2/113,0.30813721009604533,0.39144897190475114,0,0,1.8101673101673101,2.130947254489711,GNG2;DUSP1
African trypanosomiasis,1/37,0.30819964303812986,0.39144897190475114,0,0,2.7870840383530737,3.2804188561600878,LAMA4
Glutamatergic synapse,2/114,0.3117826420840456,0.39373693657470904,0,0,1.7939139941690962,2.0907152597192966,GRK3;GNG2
Primary immunodeficiency,1/38,0.3150611495175608,0.3956165570646644,0,0,2.7116202496913155,3.131890295718747,TAP1
Ferroptosis,1/41,0.3352420349621892,0.4185790380036373,0,0,2.5078680203045685,2.7408552681952725,TF
Tryptophan metabolism,1/42,0.3418366468986575,0.4244151627224905,0,0,2.4465766992695306,2.626209979517433,ALDH2
Fatty acid degradation,1/43,0.3483661651472519,0.4301057122767747,0,0,2.3882040125694948,2.518363886481836,ALDH2
cAMP signaling pathway,3/216,0.36109662870439546,0.44334641635373,0,0,1.4148790176959192,1.4412094732521261,JUN;PIK3R1;FOS
Carbohydrate digestion and absorption,1/47,0.3738459943589709,0.4539558502930361,0,0,2.1800926947693666,2.145017938066358,PIK3R1
Pyruvate metabolism,1/47,0.3738459943589709,0.4539558502930361,0,0,2.1800926947693666,2.145017938066358,ALDH2
Vascular smooth muscle contraction,2/133,0.3799989556459923,0.4564845198896693,0,0,1.5322480137093004,1.4825829134193798,ACTA2;MYLK
"Valine, leucine and isoleucine degradation",1/48,0.3800595097723944,0.4564845198896693,0,0,2.133599740792742,2.064102922116796,ALDH2
Cocaine addiction,1/49,0.3862116748146341,0.4613663791028872,0,0,2.0890439932318103,1.9874531142481775,JUN
Arginine and proline metabolism,1/50,0.39230309216925463,0.46363092710911913,0,0,2.0463068476121413,1.914771355908193,ALDH2
Vibrio cholerae infection,1/50,0.39230309216925463,0.46363092710911913,0,0,2.0463068476121413,1.914771355908193,ARF1
Endocrine and other factor-regulated calcium reabsorption,1/53,0.4102187971882732,0.4822252881840871,0,0,1.9279578289730575,1.717934990867154,ESR1
Adrenergic signaling in cardiomyocytes,2/150,0.43855675022045876,0.5128097449667798,0,0,1.3550744622173194,1.1169418833292173,PPP2R1B;TPM3
Parkinson disease,3/249,0.4485395075904751,0.5179740446905747,0,0,1.2230143839899938,0.980562193995198,KLC2;DUSP1;UBE2L6
Long-term depression,1/60,0.45000459991217345,0.5179740446905747,0,0,1.6986148154521208,1.356339639850197,PPP2R1B
Mineral absorption,1/60,0.45000459991217345,0.5179740446905747,0,0,1.6986148154521208,1.356339639850197,TF
Cytosolic DNA-sensing pathway,1/63,0.4662272355021483,0.5311145311648184,0,0,1.6161781562141804,1.2332766761682552,CXCL10
Lysine degradation,1/63,0.4662272355021483,0.5311145311648184,0,0,1.6161781562141804,1.2332766761682552,ALDH2
Cortisol synthesis and secretion,1/65,0.47677692695547874,0.540347183882876,0,0,1.565513959390863,1.159586453002292,NR4A1
Glycolysis / Gluconeogenesis,1/67,0.4871191419956142,0.5464636059950798,0,0,1.5179203199507767,1.0917589397373917,ALDH2
Long-term potentiation,1/67,0.4871191419956142,0.5464636059950798,0,0,1.5179203199507767,1.0917589397373917,RPS6KA3
Fc epsilon RI signaling pathway,1/68,0.4922137176728752,0.5466293045512836,0,0,1.4951890294719297,1.059853187664649,PIK3R1
Mitophagy,1/68,0.4922137176728752,0.5466293045512836,0,0,1.4951890294719297,1.059853187664649,JUN
Renin secretion,1/69,0.4972579405637863,0.5494700243229839,0,0,1.4731263063601074,1.029194379515607,AQP1
Synaptic vesicle cycle,1/78,0.5404701953926593,0.5942483242874512,0,0,1.3003493967960973,0.8001255112715814,SNAP25
Insulin secretion,1/86,0.575767323420109,0.6299236558210103,0,0,1.1774858166616902,0.6500329906392318,SNAP25
Cardiac muscle contraction,1/87,0.5799853520992417,0.6314126246991745,0,0,1.1637350962106008,0.6339475224236494,TPM3
Gap junction,1/88,0.5841616516113389,0.6328417892456172,0,0,1.1503004842756286,0.6183756974104047,EGFR
GABAergic synapse,1/89,0.5882966327203135,0.6342124674692161,0,0,1.1371712044300877,0.6032965943094887,GNG2
Bile secretion,1/90,0.592390702164663,0.6355259474679152,0,0,1.1243369645810757,0.58869034541816,AQP1
Phosphatidylinositol signaling system,1/97,0.6199370002177738,0.6563888888522843,0,0,1.0419839255499155,0.49821150444544404,PIK3R1
Aldosterone synthesis and secretion,1/98,0.6237179486831661,0.6563888888522843,0,0,1.031189491862473,0.48678023663841374,NR4A1
Inflammatory mediator regulation of TRP channels,1/98,0.6237179486831661,0.6563888888522843,0,0,1.031189491862473,0.48678023663841374,PIK3R1
mRNA surveillance pathway,1/98,0.6237179486831661,0.6563888888522843,0,0,1.031189491862473,0.48678023663841374,PPP2R1B
Thermogenesis,2/232,0.6716366102666964,0.7034677292366821,0,0,0.8683229813664596,0.345625406750394,RPS6KA3;PPARG
Pathways of neurodegeneration,4/475,0.6952505876775168,0.7247659428147699,0,0,0.8462363473198065,0.30759247596074907,KLC2;FZD4;UBE2L6;FADD
Lysosome,1/128,0.7212923540600442,0.7483831467007971,0,0,0.7864023342259883,0.2569260883564558,CTSD
Natural killer cell mediated cytotoxicity,1/131,0.7295409255233386,0.7534044137413917,0,0,0.7681374463100351,0.24222431776128017,PIK3R1
Systemic lupus erythematosus,1/135,0.7401623692877073,0.7608180633143409,0,0,0.745056443669975,0.22417682877072753,C3
Spinocerebellar ataxia,1/143,0.7601760907860682,0.7777727595542642,0,0,0.7027954529205691,0.19271014955075425,PIK3R1
Retrograde endocannabinoid signaling,1/148,0.7718978649398348,0.7861263970124585,0,0,0.6787181877827273,0.1757222000911549,GNG2
Huntington disease,2/306,0.8089520917893323,0.8200844600249653,0,0,0.6544709989258861,0.13875805021466703,KLC2;PPARG
Olfactory transduction,3/440,0.8141582261666318,0.8215934611087929,0,0,0.6817461714486887,0.14016738837544981,RGS2;GRK3;NCALD
Alcoholism,1/186,0.8442063722761229,0.8480436739682872,0,0,0.5382631362326794,0.09115932828441374,GNG2
Amyotrophic lateral sclerosis,1/364,0.9741363503550603,0.9741363503550603,0,0,0.27183230551943055,0.00712309238546231,KLC2
